Cargando…

Constitutive and ligand-induced EGFR signaling triggers distinct and mutually exclusive downstream signaling networks

EGFR overexpression plays an important oncogenic role in cancer. Regular EGFR protein levels are increased in cancer cells and the receptor then becomes constitutively active. However, downstream signals generated by constitutively activated EGFR are unknown. Here we report that the overexpressed EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Sharmistha, Li, Li, Puliyappadamba, VineshkumarThidil, Guo, Gao, Hatanpaa, Kimmo J., Mickey, Bruce, Souza, Rhonda F., Vo, Peggy, Herz, Joachim, Chen, Mei-Ru, Boothman, David A., Pandita, Tej K., Wang, David H., Sen, Ganes C., Habib, Amyn A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268886/
https://www.ncbi.nlm.nih.gov/pubmed/25503978
http://dx.doi.org/10.1038/ncomms6811
Descripción
Sumario:EGFR overexpression plays an important oncogenic role in cancer. Regular EGFR protein levels are increased in cancer cells and the receptor then becomes constitutively active. However, downstream signals generated by constitutively activated EGFR are unknown. Here we report that the overexpressed EGFR oscillates between two distinct and mutually exclusive modes of signaling. Constitutive or non-canonical EGFR signaling activates the transcription factor IRF3 leading to expression of IFI27, IFIT1, and TRAIL. Ligand-mediated activation of EGFR switches off IRF3 dependent transcription, activates canonical ERK and Akt signals, and confers sensitivity to chemotherapy and virus-induced cell death. Mechanistically, the distinct downstream signals result from a switch of EGFR associated proteins. EGFR constitutively complexes with IRF3 and TBK1 leading to TBK1 and IRF3 phosphorylation. Addition of EGF dissociates TBK1, IRF3, and EGFR leading to a loss of IRF3 activity, Shc-EGFR association and ERK activation. Finally, we provide evidence for non-canonical EGFR signaling in glioblastoma.